Literature DB >> 126052

Alzheimer degeneration in Down syndrome. Electrophysiologic alterations and histopathologic findings.

D R Crapper, A J Dalton, M Skoptiz, J W Scott, V C Hachinski.   

Abstract

Progressive electroencephalographic disorganization and decreased voltage amplitude in the late components of the averaged visual evoked potentials were recorded in the last two years of life of a patient with Down disease and Alzheimer degeneration. Taken together with quantitative histopathologic findings, the electrophysiologic alterations are interpreted in terms of recent evidence from an experimental animal model of dementia. Neurons with neurofibrillary degeneration become electrically inactive and contribute to the loss of voltage generators associated with neuron death in Alzheimer disease. Loss of voltage generators may result in disfacillitation and disinhibition of surviving neurons, thus causing the loss of normal rhythms.

Entities:  

Mesh:

Year:  1975        PMID: 126052     DOI: 10.1001/archneur.1975.00490510074006

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  10 in total

1.  A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease.

Authors:  Walter J Lukiw; Jian-Guo Cui; Victor L Marcheselli; Merete Bodker; Anja Botkjaer; Katherine Gotlinger; Charles N Serhan; Nicolas G Bazan
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

2.  Aluminum, altered transcription, and the pathogenesis of Alzheimer's disease.

Authors:  D R Crapper McLachlan; W J Lukiw; T P Kruck
Journal:  Environ Geochem Health       Date:  1990-03       Impact factor: 4.609

Review 3.  Neuropathological correlates of amyloid PET imaging in Down syndrome.

Authors:  Eric E Abrahamson; Elizabeth Head; Ira T Lott; Benjamin L Handen; Elliott J Mufson; Bradley T Christian; William E Klunk; Milos D Ikonomovic
Journal:  Dev Neurobiol       Date:  2019-08-17       Impact factor: 3.964

4.  Down's syndrome and the links with Alzheimer's disease.

Authors:  A J Holland; C Oliver
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-08       Impact factor: 10.154

Review 5.  Neuropsychological evaluation and rehabilitation in mental retardation.

Authors:  I Jakab
Journal:  Neuropsychol Rev       Date:  1990-06       Impact factor: 7.444

6.  Intranuclear aluminum content in Alzheimer's disease, dialysis encephalopathy, and experimental aluminum encephalopathy.

Authors:  D R Crapper; S Quittkat; S S Krishnan; A J Dalton; U De Boni
Journal:  Acta Neuropathol       Date:  1980       Impact factor: 17.088

Review 7.  Gait dyspraxia as a clinical marker of cognitive decline in Down syndrome: A review of theory and proposed mechanisms.

Authors:  Amelia J Anderson-Mooney; Frederick A Schmitt; Elizabeth Head; Ira T Lott; Kenneth M Heilman
Journal:  Brain Cogn       Date:  2016-02-27       Impact factor: 2.310

Review 8.  Docosanoids and elovanoids from omega-3 fatty acids are pro-homeostatic modulators of inflammatory responses, cell damage and neuroprotection.

Authors:  Nicolas G Bazan
Journal:  Mol Aspects Med       Date:  2018-10-01

9.  The limbic system in Alzheimer's disease. A neuropathologic investigation.

Authors:  M W Hopper; F S Vogel
Journal:  Am J Pathol       Date:  1976-10       Impact factor: 4.307

Review 10.  Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection.

Authors:  Nicolas G Bazan
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2009-06-11       Impact factor: 4.006

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.